Table 7.
Prevalence of Adverse Events among Newer Antidepressants: Unadjusted Frequency (%) of Common Adverse Events as Reported in Product Monographs.
| Nausea | Constipation | Diarrhea | Dry Mouth | Headaches | Dizziness | Somnolence | Nervousness | Anxiety | Agitation | Insomnia | Fatigue | Sweating | Asthenia | Tremor | Anorexia | Increased Appetite | Weight Gain | Male Sexual Dysfunction | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citalopram | 21 | 8 | 19 | 3 | 3 | 2 | 5 | 11 | 8 | 4 | 9 | ||||||||
| Escitalopram | 15 | 4 | 8 | 7 | 3 | 6 | 4 | 2 | 2 | 8 | 5 | 3 | 2 | 2 | 2 | 10 | |||
| Fluoxetine | 21 | 10 | 13 | 14 | 12 | 16 | 8 | 9 | 10 | 11 | 2 | ||||||||
| Fluvoxamine | 37 | 18 | 6 | 26 | 22 | 15 | 26 | 2 | 2 | 16 | 14 | 11 | 5 | 11 | 15 | 1 | |||
| Paroxetine | 26 | 14 | 11 | 18 | 18 | 13 | 23 | 5 | 5 | 2 | 13 | 11 | 15 | 8 | 1 | 16 | |||
| Sertralinea | 26 | 8 | 18 | 16 | 20 | 12 | 13 | 3 | 3 | 6 | 16 | 11 | 8 | 11 | 3 | 1 | 16 | ||
| Desvenlafaxineb | 22 | 9 | 11 | 13 | 4 | <1 | 3 | 9 | 7 | 10 | 2 | 6 | |||||||
| Duloxetine | 20 | 11 | 8 | 15 | 8 | 7 | 3 | 11 | 8 | 6 | 3 | 10 | |||||||
| Levomilnacipran | 17 | 9 | 10 | 17 | 8 | 2 | 6 | 9 | 11 | ||||||||||
| Milnacipran | 12 | 7 | 9 | 10 | 4 | 7 | 3 | 4 | 3 | ||||||||||
| Venlafaxine IR | 37 | 15 | 8 | 22 | 25 | 19 | 23 | 13 | 6 | 2 | 18 | 12 | 12 | 5 | 11 | 18 | |||
| Venlafaxine XR | 31 | 8 | 8 | 12 | 26 | 20 | 17 | 10 | 2 | 3 | 17 | 14 | 8 | 5 | 8 | 16 | |||
| Agomelatinec | C | C | C | C | C | C | C | C | C | C | |||||||||
| Bupropion SRd | 11 | 7 | 4 | 13 | 28 | 7 | 3 | 5 | 5 | 2 | 8 | 2 | 2 | 3 | |||||
| Bupropion XL | 13 | 9 | 26 | 34 | 6 | 5 | 2 | 16 | 3 | ||||||||||
| Mirtazapine | 13 | 25 | 7 | 54 | 8 | 7 | 17 | 12 | |||||||||||
| Moclobemide | 5 | 4 | 2 | 9 | 8 | 5 | 4 | 4 | 3 | 5 | 7 | 3 | 2 | 1 | 5 | ||||
| Vilazodonee | 24 | 29 | 7 | 14 | 8 | 5 | 6 | 3 | 3 | 2 | 5 | ||||||||
| Vortioxetinef | 23 | 4 | 5 | 6 | 5 | 3 | 3 | 3 | 2 | <1 |
When data from multiple doses were reported separately, the data from the minimum therapeutic dose were used (indicated by footnotes). Data sources and references are available in Supplemental Table S3. Clear cells represent 0% to 9%; shaded cells, 10% to 29%; and black cells, 30% and higher.
aData from all indications.
bData from 50-mg dose.
cC, common effects, ≥1% and <10%.
dData from 100- to 150-mg dose.
eData from 40-mg dose.
fData from 10-mg dose.